US FDA urged to revise or withdraw drug/device draft classification guides
This article was originally published in Clinica
Executive Summary
Two draft guidelines by the US Food and Drug Administration on classifying medical products as drugs or medical devices has drawn concern from stakeholders, who feel the documents could result in numerous products currently classified as medical devices having to be reclassified as drugs.
You may also be interested in...
Patient Voice Makes Impact In Scientific Advice From EU HTA Network
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Global Pharma Guidance Tracker – November 2019
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Global Medtech Guidance Tracker: November 2019
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: